Pfizer, Astellas’ Xtandi significantly improves OS in phase 3 prostate cancer study

This article was originally published here

The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The OS was a major

The post Pfizer, Astellas’ Xtandi significantly improves OS in phase 3 prostate cancer study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply